Clinical trial · no report yet · Phase 3
NCT04025879
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
- NCT04025879 ↗
- Active not recruiting
- Bristol-Myers Squibb
- 6 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-IIIB Non-small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Nivolumab; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed; Placebo; Docetaxel
- Arms
- Neoadj. Nivo+ Pt-based Doublet Chemo followed by Adj. Nivo · Experimental
- Neoadj. Plac. + Pt-based Doublet Chemo followed by Adj.Plac. · Placebo comparator
- Enrollment
- 461
- Primary outcomes
- Event-Free Survival (EFS) by BICR
- Sponsor
- Bristol-Myers Squibb
- Start
- Nov 5, 2019
- Primary completion
- Jul 26, 2023
- Results posted
- Yes
- Registry record
- NCT04025879 · updated Aug 26, 2026
Publications
linked from the registry- Cascone T, Awad MM, Spicer JD, He J, Lu S, Tanaka F, Cornelissen R, Petruzelka LB, Gao Y, Pujol JL, Ito H, de Oliveira Muniz Koch L, Ciuleanu TE, Wu L, Bohnet S, Watanabe Y, Taube JM, Deutsch JS, Erdmann CC, Meadows-Shropshire S, Neely J, Ip V, Hung YH, Sathyanarayana P, Bhatia S, Chu K, Blum SI, Lucherini S, Eddy N, Yadav A, Provencio M. Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. Nature. 2026 Aug 12. doi: 10.1038/s41586-026-10925-6. Online ahead of print. PubMed 42587156
- Provencio M, Awad MM, Spicer JD, Janssens A, Moiseyenko F, Gao Y, Watanabe Y, Alexandru A, Guisier F, Frost N, Franke F, Hiltermann TJN, He J, Tanaka F, Lu S, Coronado Erdmann C, Sathyanarayana P, Tran P, Devas V, Cascone T. Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis. Nat Cancer. 2026 Jan;7(1):169-181. doi: 10.1038/s43018-025-01104-z. Epub 2026 Jan 8. PubMed 41507539
- Tanaka F, Watanabe Y, Sugawara S, Okami J, Muto S, Okada M, Horio Y, Tsuboi M, Sato Y, Takamochi K, Horinouchi H, Tambo Y, Seike M, Okishio K, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Ito H. Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From CheckMate 77T. Cancer Sci. 2026 Mar;117(3):759-768. doi: 10.1111/cas.70300. Epub 2025 Dec 23. PubMed 41431434
- Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Karaseva N, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Ciuleanu TE, de Oliveira Muniz Koch L, Janssens A, Alexandru A, Bohnet S, Moiseyenko FV, Gao Y, Watanabe Y, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Blum SI, Provencio Pulla M; CheckMate 77T Investigators. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926. PubMed 38749033
- Leal TA, Ramalingam SS. Neoadjuvant therapy gains FDA approval in non-small cell lung cancer. Cell Rep Med. 2022 Jul 19;3(7):100691. doi: 10.1016/j.xcrm.2022.100691. PubMed 35858590
- Hong WX, Sagiv-Barfi I, Czerwinski DK, Sallets A, Levy R. Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer. Cancer Res. 2022 Apr 1;82(7):1396-1408. doi: 10.1158/0008-5472.CAN-21-1382. PubMed 35135810